1/51
Comprehensive vocabulary flashcards covering cancer biological therapies, immunologic checkpoint inhibitors, epigenetic modifications and epidrugs, G-quadruplex structures, antigene/antisense oligonucleotides, and photodynamic therapy.
Immunotherapy (Biological Therapy)
A major branch of cancer treatment—referred to as the fifth pillar of oncology—designed to restore, boost, or 'weaponize' the patient's immune system to recognize and destroy cancer cells.
Innate Immunity
The non-specific first line of host defense against potential pathogens and abnormal cells, utilizing physical barriers (such as skin and saliva) and rapid-response cells (including macrophages, neutrophils, basophils, and mast cells).
Adaptive Immunity
The antigen-specific second line of defense that builds immunological memory to mount enhanced responses; driven primarily by T-lymphocytes (cell-mediated killing) and B-lymphocytes (antibody production).
Interleukin 2 (IL-2)
A synthesized cytokine used in cancer immunotherapy that boosts adaptive immune responses by stimulating the production and activation of antigen-fighting T-cells and encouraging B-cells to produce antibodies.
Interferon-α (IFN-α)
A synthetic cytokine employed in cancer immunotherapy that stimulates the generation and activity of innate immune cells, including dendritic cells and macrophages, to target and destroy abnormal cells.
Immune Checkpoint Blockade
An immunotherapeutic strategy using monoclonal antibodies to block inhibitory receptor pathways (such as CTLA-4 and PD-1), effectively 'releasing the brakes' on T-cells to attack cancer cells.

PD-1 (Programmed Death 1)
An inhibitory checkpoint receptor expressed on activated T-cells, B-cells, and natural killer cells that, upon binding its ligand, downregulates T-cell cytotoxicity to maintain self-tolerance and limit autoimmunity.
PD-L1
An immune inhibitory ligand frequently upregulated on tumor cell surfaces that binds PD-1 on T-cells, signaling the immune system to stand down and allowing malignant cells to evade immunosurveillance.
Pembrolizumab (Keytruda®)
A monoclonal antibody checkpoint inhibitor targeting the PD-1 receptor on T-cells, disrupting the inhibitory signal from PD-L1 and restoring anti-tumor cytotoxic T-cell activity.
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4)
A key negative regulatory receptor on T-cells that dampens immune response potency; targeted by blocking antibodies to unleash robust anti-tumor immune responses.
Ipilimumab (Yervoy®)
An FDA-approved monoclonal antibody that blocks the CTLA-4 receptor, relieving inhibitory control over T-cells; approved for the intravenous treatment of melanoma.
Sipuleucel-T (Provenge®)
The only FDA-approved therapeutic cancer vaccine in the US, indicated for advanced hormone-refractory prostate cancer; produced by exposing a patient's extracted antigen-presenting cells ex vivo to prostatic acid phosphatase (PAP).
Prostatic Acid Phosphatase (PAP)
A tumor-associated protein antigen overexpressed on prostate cancer cells used to pulse and activate dendritic cells ex vivo during the manufacture of the Provenge cancer vaccine.
CAR-T Therapy
Chimeric Antigen Receptor T-cell therapy; an adoptive cell transfer approach where patient T-cells are harvested, genetically engineered ex vivo to express a synthetic tumor-targeting receptor, and reinfused to destroy cancer cells.
Tisagenlecleucel (Kymriah®)
The first CAR-T cell therapy approved by the FDA (August 2017), genetically engineered to target the CD19 antigen domain on B-cell malignancies.
CD19
A cell-surface antigen domain widely expressed on normal and malignant B-cells, serving as the therapeutic target for approved CAR-T therapies including Kymriah and Yescarta.
Epigenetics
The study of heritable changes in gene expression and function that occur without altering the underlying primary DNA sequence.
Euchromatin
A relaxed, open chromatin conformation characterized by hyperacetylated histones that permits transcription factor and RNA polymerase access, facilitating active gene expression.
Heterochromatin
A condensed, tightly packaged chromatin structure resulting from strong electrostatic interactions between basic histone lysine residues and DNA, causing transcriptional repression.
Epigenetic Writers
Enzymes that synthesize and place chemical marks onto DNA or histone tails, including DNA methyltransferases (DNMTs) and histone acetyltransferases (HATs).
Epigenetic Erasers
Enzymes responsible for removing covalent modifications from DNA or histone proteins, such as histone deacetylases (HDACs) and demethylases.
CpG Islands
Short stretches of DNA enriched in cytosine-guanine dinucleotides that are clustered in or near the promoter regions of approximately half of all human genes.
Cancer Genome DNA Methylation Pattern
An aberrant epigenetic state characterized by global DNA hypomethylation (20–50% less 5-MeC across the genome) alongside localized hypermethylation of CpG islands in tumor suppressor gene promoters.
DNA Methyltransferase (DNMT)
A family of writer enzymes that catalyze the transfer of a methyl group to cytosine bases in DNA (forming 5-methylcytidine); frequently overexpressed in cancer to hypermethylate and silence tumor suppressor promoters like p16 and RB1.
Azacitidine and Decitabine
FDA-approved cytidine nucleoside analogs (approved in 2004 and 2006, respectively) that incorporate into replicating DNA to irreversibly inhibit DNMTs, reactivating silenced tumor suppressor genes.
Histone Deacetylases (HDACs)
Eraser enzymes that remove acetyl groups from positively charged lysine residues on histone tails, tightening chromatin compaction and repressing tumor suppressor genes such as p53, p16, RB1, and BRCA1.

Hydroxamic Acid HDAC Inhibitors
A class of selective HDAC epidrugs (including vorinostat, belinostat, and panobinostat) featuring a hydroxamic acid pharmacophore that chelates the catalytic Zn2+ ion in the enzyme's active site.
Romidepsin
A peptidic natural product approved by the FDA in 2009 that functions as an epigenetic eraser inhibitor targeting histone deacetylases (HDACs).
6-Shogaol
A bioactive component found in ginger that acts as a histone acetyltransferase (HAT) inhibitor, downregulating the PI3K pathway and suppressing oncogenic factors such as cyclin D, Bcl-2, c-MYC, and survivin.

G-Quadruplex (G4)
A four-stranded non-canonical nucleic acid secondary structure formed by guanine-rich tracts, held together by planar, Hoogsteen base-paired G-tetrads and stabilized by monovalent cations (K+).
Hoogsteen Base Pairing
An alternative, non-Watson-Crick hydrogen bonding motif utilizing the N7 position and major groove edge of purine bases, critical for stabilizing both G-tetrads in G4 DNA and triplex DNA.
Telomerase Enzyme
A reverse transcriptase overexpressed in approximately 90% of human cancers that elongates chromosome ends; its activity is impeded when telomeric single-stranded overhangs are stabilized into G-quadruplexes.
c-MYC Promoter G4
A regulatory quadruplex element located upstream of the transcription start site of the c-MYC oncogene that functions as a transcriptional silencer when stabilized by interactive ligand molecules.
TMPyP4
A cationic porphyrin small molecule that binds and stabilizes G-quadruplex structures, thereby shutting down transcription of the c-MYC oncogene.
Quarfloxin (CX-3543)
A synthetic fluoroquinolone G4-interactive drug that disrupts nucleolin binding to rDNA quadruplexes, selectively blocking RNA Polymerase I transcription and ribosomal RNA synthesis; reached Phase II trials.
Naphthalene Diimides (NDIs)
A favored synthetic chemotype for G4 targeting characterized by a planar, electron-deficient aromatic core for tetrad end-stacking and basic/cationic side chains for groove and backbone electrostatic interactions.
CM03
An in silico-designed tri-substituted naphthalene diimide that stabilizes G4 elements in the K-RAS promoter, suppressing multiple survival pathways in pancreatic ductal adenocarcinoma (PDAC).

Telomestatin
A potent natural macrocyclic product isolated from Streptomyces anulatus that selectively binds and stabilizes telomeric G-quadruplex structures, inhibiting telomerase and tumor cell proliferation.
Anti-Gene Therapy
A therapeutic strategy that targets double-stranded genomic DNA at the transcriptional level using synthetic oligonucleotides to form local three-stranded triplex DNA, blocking gene expression.
Triplex-Forming Oligonucleotides (TFOs)
Short synthetic single-stranded oligonucleotides (∼20–30 nucleotides) that bind into the major groove of double-stranded DNA via sequence-specific Hoogsteen hydrogen bonding to inhibit transcription factor binding or RNA polymerase elongation.
Anti-Sense Therapy
A post-transcriptional gene silencing approach using single-stranded oligonucleotides that hybridize via Watson-Crick base pairing to complementary target mRNA, blocking translation and triggering RNA degradation.
Antisense Oligonucleotides (ASOs)
Synthetic oligonucleotides (∼15–20 nucleotides in length) designed to be sequence-complementary to specific disease-causing mRNAs, inhibiting translation through steric hindrance or RNase H recruitment.

Phosphorothioate (PS) Backbone
A first-generation chemical modification in which a non-bridging oxygen atom in the phosphodiester linkage is substituted with a sulfur atom, imparting resistance to nuclease degradation and prolonging in vivo half-life.
RNase H
A cellular endonuclease that selectively hydrolyzes the RNA strand of an RNA-DNA heteroduplex formed between target mRNA and an ASO, freeing the intact ASO to destroy additional mRNA molecules.
Mipomersen (Kynamro®)
An FDA-approved (2013) phosphorothioate antisense oligonucleotide targeting the mRNA encoding apolipoprotein B, indicated for lowering low-density lipoprotein levels in familial hypercholesterolemia.
Photodynamic Therapy (PDT)
A localized anticancer treatment combining a non-toxic photosensitizing drug, a specific activating wavelength of non-thermal light, and tissue oxygen to produce cytotoxic reactive oxygen species.
Drug-Light Interval
The precise period of time between the administration of a photosensitizer and the delivery of activating light, allowing the agent to accumulate preferentially within tumor tissue.
Reactive Oxygen Species (ROS)
Highly reactive oxygen radicals (such as singlet oxygen, 1O2) produced when an excited triplet-state photosensitizer transfers energy to ground-state oxygen, inducing direct tumor necrosis, apoptosis, and vascular collapse.
Tissue Penetration Limit of PDT Light
The physical depth limit (∼1/3 inch or 1cm) that activation light can traverse through human tissue, restricting standard PDT to superficial tumors, skin cancers, and linings of accessible internal organs.
Porfimer Sodium (Photofrin®)
An FDA-approved photosensitizer used in PDT for the palliative relief of obstructing esophageal cancer, obstructing non-small cell lung cancer, and the ablation of precancerous lesions in Barrett's esophagus.
Aminolevulinic Acid (ALA / Levulan®)
A topical prodrug photosensitizer applied to the face or scalp and activated with blue light to selectively treat precancerous actinic keratosis.
Photoimmunotherapy (PIT)
An emerging hybrid cancer modality combining the target specificity of a monoclonal antibody conjugated directly to a photosensitizer, achieving selective tumor destruction upon illumination alongside localized immune activation.